1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Portola's Xarelto/Eliquis Antidote To Be Refiled Next Year

 
• By Sukaina Virji

Portola plans to resubmit the crucial BLA for its anticoagulant reversal agent AndexXa 'in the second quarter of 2017' after its unexpected August CRL. An approval would shore up the commercial success of Xarelto and Eliquis. Meanwhile, it has filed an NDA for its own Factor Xa inhibitor, betrixaban.

Portola Pharmaceuticals Inc. suffered a surprise setback in August this year when its reversal agent AndexXa (andexanet) was the subject of a complete response letter from the US FDA. (Also see "Portola Seeks Narrower Label For AndexXa Antidote After FDA Rebuff" - Scrip, 19 August, 2016.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.